Quercetin-loaded solid lipid nanoparticles improve osteoprotective activity in an ovariectomized rat model: a preventive strategy for post-menopausal osteoporosis

被引:37
作者
Ahmad, Naseer [1 ]
Banala, Venkatesh Teja [2 ]
Kushwaha, Priyanka [1 ]
Karvande, Anirudha [1 ]
Sharma, Shweta [2 ]
Tripathi, Ashish Kumar [1 ]
Verma, Ashwni [2 ]
Trivedi, Ritu [1 ]
Mishra, Prabhat Ranjan [2 ]
机构
[1] CSIR, Cent Drug Res Inst, Div Endocrinol, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India
[2] CSIR, Cent Drug Res Inst, Div Pharmaceut, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India
关键词
CONTROLLED DRUG-DELIVERY; BONE-MARROW CULTURES; SPRAGUE-DAWLEY RATS; ORAL BIOAVAILABILITY; OSTEOCLASTOGENESIS; KAEMPFEROL; FLAVONOIDS; CISPLATIN; ESTROGEN; GROWTH;
D O I
10.1039/c6ra17141a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A formulation of quercetin-based solid lipid nanoparticles (QSLNs) was developed to increase the bioavailability of quercetin, with an aim to evaluate its effects on bone health in comparison to free quercetin (Q). The QSLNs were prepared by emulsification solvent evaporation followed by a cold homogenization method. The QSLNs were spherical when observed under atomic force microscopy, with an average diameter of 172.9 +/- 12.65 nm. This formulation was pharmaceutically characterized and then evaluated for osteoprotective activity in ovariectomized (OVx) rats. A single oral dose of QSLNs (5 mg kg(-1) d(-1)) significantly increased the bioavailability compared to free quercetin. The oral administration of QSLNs to ovariectomized rats increased serum quercetin levels by 3.5-fold compared to free quercetin. After 12 weeks of treatment, the bone mineral density of the femur, tibia and lumbar spine L-5 measured by micro-computed tomography (mu CT) was restored in the QSLNs group, and was equivalent to the sham control group compared to in the OVx group, but the QSLNs had no effect on adipogenesis and uterine weight in OVx rats mu CT analysis showed that the QSLNs group had an improved trabecular microarchitecture in the distal femoral, proximal tibial and lumbar spine cancellous bones. The developed quercetin formulation based on solid lipid nanoparticles inhibited bone loss in osteopenic rats. Q and QSLNs inhibited the receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclast cells differentiation and the expression of osteoclast-specific genes in in vitro experiments using bone marrow cells treated with RANKL and M-CSF. The data from this study suggest that, overall, QSLNs treatment recovers bone loss (femur, BV/TV; similar to 21%, p < 0.01) more so than in the Q treatment group, while both inhibit bone loss without showing any hyperplasic effect on the uteri in OVx rats.
引用
收藏
页码:97613 / 97628
页数:16
相关论文
共 69 条
[11]  
Cipák L, 2003, LEUKEMIA RES, V27, P65, DOI 10.1016/S0145-2126(02)00063-2
[12]   Phyto-oestrogens and bone health [J].
Coxam, Veronique .
PROCEEDINGS OF THE NUTRITION SOCIETY, 2008, 67 (02) :184-195
[13]  
Delmas P D, 1999, J Epidemiol Biostat, V4, P155
[14]   Predicting oral drug absorption and hepatobiliary clearance: Human intestinal and hepatic in vitro cell models [J].
Fearn, RA ;
Hirst, BH .
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2006, 21 (02) :168-178
[15]   DISPOSITION OF QUERCETIN IN MAN AFTER SINGLE ORAL AND INTRAVENOUS DOSES [J].
GUGLER, R ;
LESCHIK, M ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 9 (2-3) :229-234
[16]  
Gupta GK, 2013, NANOMEDICINE-UK, V8, P757, DOI [10.2217/NNM.12.171, 10.2217/nnm.12.171]
[17]   Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships [J].
Heim, KE ;
Tagliaferro, AR ;
Bobilya, DJ .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2002, 13 (10) :572-584
[18]  
Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
[19]   THE LONG-TERM RISKS AND BENEFITS OF HORMONE REPLACEMENT THERAPY [J].
HILLARD, TC ;
WHITCROFT, S ;
ELLERINGTON, MC ;
WHITEHEAD, MI .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1991, 16 (04) :231-245
[20]   Dietary flavonoids: Intake, health effects and bioavailability [J].
Hollman, PCH ;
Katan, MB .
FOOD AND CHEMICAL TOXICOLOGY, 1999, 37 (9-10) :937-942